Home/ Peptides/ BPC 157

BAck to all peptides

Bpc 157

BPC-157 is a regenerative peptide renowned for its ability to accelerate healing and protect the body at the cellular level.

Originally derived from a naturally occurring gastric protein, this 15-amino-acid sequence has been shown in research to enhance tissue repair, safeguard the digestive system, and reduce inflammation.

Book a Consultation
Man standing confidently in modern neutral-toned outdoor space, representing Paragon’s elite precision care philosophy

Overview

Body Protection Compound-157 (BPC-157) is a synthetic pentadecapeptide consisting of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a naturally occurring protein found in human gastric juice. Originally isolated from gastric secretions, BPC-157 represents the stable, active terminal fragment of the larger Body Protection Compound that contributes to gastric cytoprotection and mucosal integrity.

This peptide has gained considerable attention in regenerative medicine due to its demonstrated pleiotropic beneficial effects in preclinical models, particularly in tissue healing, vascular repair, and inflammatory modulation. BPC-157 exhibits remarkable stability in human gastric juice and maintains bioactivity across various physiological conditions, making it unique among therapeutic peptides.

Patient consulting with Dr. Ched Garten at Paragon, symbolizing advanced non-surgical care for joint, tendon, muscle, and pain issues.

Chemical structure & Properties

  • Molecular Formula: C62H98N16O22
  • Molecular Weight: 1419 Da
  • Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
  • Half-life: Less than 30 minutes (hepatic metabolism)
  • Stability: Resistant to gastric acid degradation, stable in human gastric juice

Mechanism of Action

BPC-157 exerts its therapeutic effects through multiple interconnected molecular pathways:

Nitric Oxide Pathway Modulation

BPC-157 activates the Src-Caveolin-1-endothelial nitric oxide synthase (eNOS) pathway, leading to:

  • Enhanced nitric oxide production
  • Improved endothelium-dependent vasodilation
  • Increased vascular endothelial cell migration
  • Stabilization of vascular tone

Angiogenesis and Vascular Repair

The peptide promotes new blood vessel formation through:

  • Upregulation of vascular endothelial growth factor (VEGF) protein and gene expression
  • Activation of VEGFR2-Akt-eNOS signaling pathways
  • Enhanced endothelial cell proliferation and migration
  • Improved collateral vessel formation

Growth Factor Modulation

BPC-157 influences cellular growth and repair by:

  • Upregulating growth hormone receptor expression in target tissues
  • Enhancing phosphorylation of extracellular signal-regulated kinases (ERK1/2)
  • Activating focal adhesion kinase (FAK) and downstream signaling
  • Promoting insulin-like growth factor-1 (IGF-1) pathway activation

Anti-inflammatory Effects

The peptide demonstrates anti-inflammatory properties through:

  • Reduction of pro-inflammatory cytokines (IL-6, TNF-α)
  • Decreased cyclooxygenase-2 (COX-2) expression
  • Inhibition of nuclear factor-kappa B (NF-κB) signaling
  • Enhanced expression of cytoprotective proteins (HSP70, HSP90)

Clinical Applications and

Research Evidence

Patient consulting with Dr. Ched Garten at Paragon, symbolizing advanced non-surgical care for joint, tendon, muscle, and pain issues.

Current Clinical Evidence

Primary Pathways: BPC-157 exerts its therapeutic effects through multiple interconnected molecular pathways.

Safety Considerations

Preclinical Safety Data

Animal studies across multiple species demonstrate:

  • No acute toxicity at doses ranging from 6 μg/kg to 20 mg/kg
  • No observable lethal dose (LD50) established
  • No significant histologic toxicity in major organs
  • Minimal adverse effects across various administration routes

Potential Concerns

Theoretical Cancer Risk:

  • Angiogenesis promotion may theoretically support tumor growth
  • No direct evidence of carcinogenesis in current studies
  • Caution advised in patients with active malignancy or cancer history
  • Minimal adverse effects across various administration routes

Drug Interactions:

  • Limited data on interactions with other medications
  • Potential synergistic effects with growth-promoting substances
  • Consultation with healthcare providers recommended

Contraindications

BPC-157 should be avoided in:

  • Active malignancy or history of cancer
  • Pregnancy and breastfeeding (insufficient safety data)
  • Individuals with known hypersensitivity to peptides
  • Patients with severe cardiovascular disease (without medical supervision)

Regulatory Status and

Legal Considerations

FDA Status

  • Classification: Category 2 bulk drug substance (2023)
  • Approval Status: Not approved for human therapeutic use
  • Compounding: Prohibited for commercial pharmaceutical compounding
  • Regulatory Position: Insufficient evidence for safety determination

WADA Status

  • Classification: Prohibited under S0: Non-Approved Substances
  • Athletic Use: Banned in competitive sports
  • Testing: Detectable in anti-doping screenings

Legal Availability

  • Commercial Status: Not legally available as prescription medication
  • Market Presence: Sold as "research chemicals" or "dietary supplements"
  • Quality Control: No regulatory oversight for purity or potency
  • Clinical Use: Limited to research settings and experimental protocols

Administration and Dosing

Considerations

The Paragon Method: Step-by-Step

Clinical Considerations

Important Notes:

  • No FDA-approved dosing guidelines exist for human use
  • Individual response may vary significantly
  • Medical supervision recommended for any therapeutic application
  • Quality and purity of commercially available products not guaranteed

Priority Research Areas

  • Large-scale human clinical trials for safety and efficacy determination
  • Standardized dosing protocols for various clinical applications
  • Long-term safety studies including carcinogenicity assessment
  • Mechanism elucidation of molecular targets and pathways
  • Drug interaction studies with commonly prescribed medications

Emerging Applications

Research is investigating potential applications in:

  • Traumatic brain injury and neuroprotection
  • Wound healing and post-surgical recovery
  • Age-related degenerative conditions
  • Metabolic disorders and diabetes complications
Man seated indoors with a soccer ball in natural light, representing Paragon’s musculoskeletal recovery expertise and regenerative treatment focus.

Conclusion

BPC-157 represents a promising therapeutic peptide with demonstrated benefits in preclinical models of tissue healing, inflammation, and vascular repair. Its unique mechanism of action through multiple molecular pathways offers potential advantages in regenerative medicine applications. However, the current evidence base remains predominantly preclinical, with limited human clinical data available.

The lack of FDA approval, potential safety concerns, and regulatory restrictions necessitate careful consideration and medical supervision for any therapeutic application. Patients interested in BPC-157 therapy should engage in thorough discussions with qualified healthcare providers to weigh potential benefits against risks and explore evidence-based treatment alternatives.

Future research will be critical in establishing the safety, efficacy, and appropriate clinical applications of BPC-157 in human medicine. Until comprehensive clinical trials are completed, its use should remain limited to research settings and experimental protocols under appropriate medical oversight.

Book a consultation
Book a consultation

BPC-157 SCIENTIFIC

DATA SUMMARY

MOLECULAR CHARACTERISTICS
PRECLINICAL EFFICACY DATA
CLINICAL EVIDENCE SUMMARY
SAFETY PROFILE
REGULATORY STATUS
Parameter
Molecular Weight
Amino Acid Length
Half-Life
Bioavailability
Detection Window
Value
1,419 Da
15 residues
<30 minutes (hepatic)
Stable in gastric juice
Up to 4 days (urine)
Application
Tendon Healing
Gastric Protection
Angiogenesis
Anti-inflammatory
Studies
8+ studies
15+ studies
6+ studies
10+ studies
Dose Range
1-20 μg/kg
10 ng/kg-10 μg/kg
0.1-100 μg local
1-10 μg/kg
Outcome
Enhanced tensile strength, accelerated repair
Reduced ulceration, improved barrier function
Increased vessel density, VEGF upregulation
Reduced IL-6, TNF-α, COX-2 expression
Study Type
Phase I Trial
Knee Pain Study
Bladder Pain Pilot
Population
42 healthy volunteers
12 patients
12 women
Results
Results not published
11/12 reported improvement
Subjective improvement
Limitations
Study terminated 2016
No standardized measures
No objective endpoints
Parameter
Acute Toxicity
Organ Toxicity
Adverse Events
Long-term Safety
Finding
No LD50 established (6 μg/kg to 20 mg/kg tested)
No histologic changes in major organs
Minimal reported in animal studies
Limited human data available
Authority
FDA
WADA
DEA
Classification
Category 2 Bulk Drug
S0 Non-approved Substance
Unscheduled
Status
Not approved for human use
Prohibited in sports
Not controlled substance

Disclaimer:  This information is provided for educational purposes only and does not constitute medical advice. BPC-157 is not approved by the FDA for human therapeutic use. Patients should consult with qualified healthcare providers before considering any peptide therapy.

The content reflects current scientific literature and regulatory status as of 2025.